Sales of over-the-counter products containing codeine in 31 countries,

2 **2013-2019:** a retrospective observational study

- 4 Georgia C Richards* (0000-0003-0244-5620)^{1,2};
- 5 $Jeffrey K Aronson (0000-0003-1139-655X)^2$;
- 6 Brian MacKenna (0000-0002-3786-9063)³;
- 7 Ben Goldacre (0000-0002-5127-4728)³;

1

3

10

20

22

- 8 FD Richard Hobbs (0000-0001-7976-7172)⁴;
- 9 *Carl Heneghan* (0000-0002-1009-1992)^{1,2}
- ¹Global Centre on Healthcare and Urbanisation, Kellogg College, University of Oxford,
- 12 60-62 Banbury Road, Oxford, OX2 6PN, UK.
- 13 ²Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health
- 14 Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road,
- 15 Oxford, OX2 6GG, UK.
- ³EBM Datalab, Nuffield Department of Primary Care Health Sciences, University of
- 17 Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.
- ⁴Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe
- 19 Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.
- *corresponding author: GC Richards, georgia.richards@kellogg.ox.ac.uk
- 23 **Word count:** 2684

25 Running heading: Trends in over-the-counter sales of codeine in 31 countries 26 27 Acknowledgements: We thank the Primary Care Research Trust of Birmingham and 28 Midlands Research Practices Consortium for providing the funding to purchase the 29 sales data from IQVIA. 30

ABSTRACT 32 33 Introduction 34 Opioid prescribing trends have been investigated in many countries. However, the 35 patterns of over-the-counter purchases of opioids without a prescription, such as 36 codeine combinations, are mostly unknown. 37 38 **Objective** 39 We aimed to assess national sales and expenditure trends of over-the-counter codeine-40 containing products purchased in countries with available data over six years. 41 42 Methods 43 We conducted a retrospective observational study using electronic point-of-sale data 44 from the human data science company, IQVIA, for countries that had such data, 45 including Argentina, Belgium, Brazil, Bulgaria, Canada, Croatia, Estonia, Finland, 46 France, Germany, Greece, Ireland, Italy, Japan, Latvia, Lithuania, Mexico, The 47 Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, South 48 Africa, Spain, Switzerland, Thailand, the UK, and the USA. We calculated annual mean 49 sales (dosage units per 1000 of the population) and public expenditure (GBP, £ per 50 1000 population) for each country between April 2013 and March 2019 and adjusted for 51 data coverage reported by *IOVIA*. We quantified changes over time and the types of 52 products sold. 53 54 **Results**

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

31.5 billion dosage units (adjusted: 42.8 billion dosage units) of codeine, costing £2.55 billion (adjusted: £3.68 billion), were sold over-the-counter in 31 countries between April 2013 and March 2019. Total adjusted sales increased by 11% (3911 dosage units/1000 population in 2013 to 4358 in 2019) and adjusted public expenditure increased by 72% (£263/1000 in 2013 to £451/1000 in 2019). Sales were not equally distributed; South Africa sold the most (36 mean dosage units/person), followed by Ireland (30 mean dosage units/person), France (20 mean dosage units/person), the UK (17.2 mean dosage units/person), and Latvia (16.8 mean dosage units/person). Types of products (n=569) and formulations (n=12) sold varied. Conclusion In many parts of the world, substantial numbers of people may be purchasing and consuming codeine from over-the-counter products. Clinicians should ask patients about their use of over-the-counter products, and public health measures are required to improve the collection of sales data and the safety of such products. Study protocol pre-registration: https://osf.io/ay4mc The pre-print version of this work is available on medRxiv: https://doi.org/10.1101/2021.04.21.21255888 **Key points** Codeine is one of the most accessible pain medicines available worldwide, yet data on its use as an over-the-counter drug has been limited.

• We found that total sales and expenditure of over-the-counter products containing codeine increased from April 2013 to March 2019, but there was substantial variation in mean sales between countries and the coverage of data reported by *IQVIA*, with South Africa, France, Japan, the UK, and Poland accounting for 90% of all sales data.

 In countries with access to over-the-counter codeine products, sales data should be collected, made available, and reviewed to inform regulatory decisions and public health measures to ensure safety.

1 Introduction

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

Prescribing patterns of opioids are documented in many countries [1–4]. However, opioids such as analgesic combinations containing codeine can be purchased over-thecounter (OTC) without a prescription or consultation with a doctor or prescriber in most countries. As the access to data on sales of OTC medicines has been limited, previous research on the use of non-prescribed codeine has relied on case reports [5,6], selfreported questionnaires [7–10], qualitative studies [11–13], and data from poisons centres, hospital admissions, or coronial systems [14–16]. Since codeine is one of the most accessible opioids worldwide, an analysis of its use is needed to gauge a more robust understanding of opioid use globally. Codeine (3-methylmorphine) is used for its analgesic, antidiarrheal, and antitussive effects [17–19]. It is often combined with other analgesics, such as paracetamol, and non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. These combinations have greater efficacy than codeine alone [17,20,21]. But most clinical trials testing the efficacy of code ine have used high doses (25–90 mg), which are not available OTC [20–22]. A Cochrane overview of systematic reviews on oral OTC analgesics for acute pain found no studies or data that could be extracted on combinations of analysesics containing low doses of codeine [22]. A systematic review of the efficacy and safety of low-dose (≤30 mg) codeine included ten RCTs [23]. It reported low- to moderate-quality evidence that combination products of low-dose codeine provided little to moderate pain relief for acute and chronic pain conditions in the short term [23]. In observational studies, products containing codeine have been

associated with dependence, misuse, death, and collateral toxicity from combinations with paracetamol and ibuprofen [15,24]. Regulation of codeine-containing products varies worldwide, making it difficult to estimate how much they are used [25]. Under the 1961 Single Convention on Narcotic Drugs, codeine is a Schedule III drug [26]. Drugs in this Schedule reportedly "are not liable to abuse and cannot produce ill effects", and thus it is not mandatory to report data on their consumption to the International Narcotics Control Board (INCB). In a report presented at the WHO's Expert Committee on Drug Dependence in October 2019, reviewing codeine formulations listed in Schedule III, the INCB reported a 64% increase in demand for codeine in the last decade [25]. Governments can also regulate codeine; for example, France (July 2017) and Australia (February 2018) have reclassified codeine to prescription-only [27,28]. A review of OTC codeine regulations in the European Union showed that more than half of member countries did not permit OTC sales of codeine as of March-August 2014 [29]. Studies have analysed the consumption of OTC cough syrup containing codeine in Taiwan [30] and the impact of rescheduling codeine to prescription-only in Australia [31,32], but the sales of OTC codeine products in other countries remains unknown. We aimed to assess trends in the sales and expenditure of products containing codeine sold OTC in countries with available data. 2 Methods

2.1 Design and data source

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

We conducted a retrospective observational study using consumer health sales data from IOVIA in the UK [33], which has previously been used in observational research on a range of medications [34–36]. The data included products sold OTC that contained codeine for adults, classified by IQVIA as pain relief or cough products. The data were collected using scan track barcodes from electronic point-of-sale (EPoS) store data in 31 countries: Argentina, Belgium, Brazil, Bulgaria, Canada, Croatia, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Japan, Latvia, Lithuania, Mexico, The Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, South Africa, Spain, Switzerland, Thailand, the UK, and the USA. The authors did not select these countries; they requested global sales data from *IOVIA* and received data for "all countries for which data is available" according to IQVIA at the time of data extraction (16 September 2019). We received information about *IQVIA*'s coverage of data (Table S1 in Supplement 1) and quarterly sales from 1 April 2013 to 31 March 2019 in three types of measurements (1) numbers of packs and bottles (liquids) sold; (2) number of tablets or millilitres (mL) of liquids sold; and (3) dosage units. For our analysis, we used dosage units as this allows liquid and solid forms to be combined. Dosage units were calculated and defined by IQVIA as "the smallest common doses for a product form", which "equates the number of mL of liquid preparations, such as 5 mL of codeine, to the standard solid dosage of one tablet". IQVIA's sample of data is based on audits, but their method of collection and coverage varies from country to country. Annual population statistics for each calendar year (2013 to 2018) were sourced from the World Bank [37].

2.2 Data analysis

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

We extracted details from the pack information and used descriptive statistics to determine the numbers and types of products sold across the 31 countries. Data on dosages were missing from the pack information for most countries, so we could not calculate oral morphine equivalents (OME), as this conversion would vary for the different products in each country. We combined the quarterly data to calculate the total dosage units sold over the study period and the totals for each year (e.g. from quarter two in 2013 to quarter one in 2014). We also calculated the mean number of dosage units sold over six years, adjusted for population. We created an annual rate of dosage units sold per 1000 of each year's population for each country to examine trends over time. To adjust for the heterogeneity of *IQVIA*'s coverage by dividing the reported sales by the percentages in Table S1 of Supplement. For public expenditure, IQVIA converted sales to pounds sterling (GBP, £) for each country on the date of data extraction (16 September 2019). Public expenditure refers to the money spent on OTC products by citizens directly from their pockets and was defined by IQVIA as the "pharmacy selling price or consumer purchase price or price to the public". We calculated annual totals, mean public expenditure for each country, adjusted for population, and a rate of GBP per 1000 population to assess changes over time. We also adjusted for the heterogeneity of IQVIA's coverage by dividing the reported expenditure by the percentages in Table S1 of Supplement.

2.3 Software and data sharing

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

We used Stata v16 and Python v3 in Jupyter Notebooks with pandas [38], seaborn [39], and matplotlib [40] libraries for analysis and figures. The information provided by IOVIA is considered commercial and requires a fee to access. Thus, we cannot openly share the data owing to contractual agreements with IQVIA. However, we have openly shared our statistical code at GitHub [41], preregistered [42] and published [43] our study protocol, and shared all our study materials via the Open Science Framework (OSF) [44]. 3 Results 31.5 billion dosage units of codeine reportedly sold OTC across 31 countries over the six-year study period (April 2013 to March 2019). After adjusting for IQVIA's data coverage, this equated to 42.8 billion dosage units. However, the distribution of reported sales was not uniform. Five countries represented 90% of OTC codeine sales reported by IQVIA; South Africa accounted for the greatest volume of sales data (34%), followed by France (20%), Japan (16.5%), the UK (14.5%), and Poland (5%). South Africa sold the most OTC codeine products (mean of 36 dosage units/person; Figure 1 and Table 1), followed by Ireland (30 dosage units/person), France (20 dosage units/person), the UK (17.2 dosage units/person), and Latvia (16.8 dosage units/person). [Figure 1 near here] [Table 1 near here]

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

Over the six-year study period, total reported sales increased by 2.8%, from 3025 dosage units/1000 population in 2013–14 to 3111 dosage units/1000 in 2018–19. After adjusting for IOVIA's data coverage, total sales increased by 11.4%, from 3911 dosage units/1000 population in 2013–14 to 4358 dosage units/1000 in 2018-19. Nationally, most (52%, n=16) countries had decreased OTC codeine sales, but this varied widely (Figure 2, and Figure S1 and S2 in Supplement 1). [Figure 2 near here] The public spent £2.55 billion on OTC codeine-containing products in 31 countries over six years; after adjusting *IQVIA*'s percentage coverage, this equated to £3.68 billion. Reported public expenditure increased by 54%, from £196/1000 population in 2013–14 to £301/1000 population in 2018–19. Adjusting for *IOVIA*'s percentage coverage, public expenditure increased by 72%, from £263/1000 population in 2013–14 to £451/1000 population in 2018–19. Ireland had the largest mean public expenditure of £7.18 per person, followed by the UK (mean of £2.39/person), Croatia (£1.87/person), Japan (£1.55/person), and South Africa (£1476/person) (Figure 3). [Figure 3 near here] Most countries (58%, 18/31) had increased public expenditure over time. There were simultaneous increases (45%, 14/31) and decreases (39%, 12/31) in both sales and

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

expenditure in most countries, while other countries (16%, 5/31) had a discordance in the direction of their sales and expenditure (Figure 4). [Figure 4 near here] There were 569 products and 12 formulations sold across 31 countries (Figure S3 in Supplement 1). Tablets (40%) were the most common formulations sold, followed by syrups (22%), soluble tablets (9%), and coated tablets (8%). Seven countries, including Argentina, Finland, Greece, Italy, Mexico, The Netherlands, and The USA, reportedly sold no codeine products in any tablet formulations OTC; instead, they sold codeine in liquid, syrup, lozenge, drop or powder formulations (Table S2 in Supplement 1). Products contained a median of three substances per combination (IQR: 2–4, range: 1– 16). Limited details were available in the pack information: the dosages of codeine were available in 17% of products (98 of 569) in 15 countries. 4 Discussion Many people have purchased non-prescribed codeine in several parts of the world. Overall, total sales and public expenditure of OTC codeine products increased over time. However, sales and expenditure were not equally distributed across the 31 countries. South Africa consistently sold the greatest volume of OTC codeine each year. This demand for OTC codeine could be driven by the incidences of painful conditions in South Africa and the growing concern of opioid misuse and dependence [45,46]. In the

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

2016 South African Demographic and Household Survey [45], the prevalence of chronic pain in the adult population was 18.3% (95% confidence interval: 17.0-19.7%). A study of admission for substance abuse treatments in South Africa found that 2.5% (n=435) of all admissions in 2014 were for codeine misuse or dependence [47]. In a 2014 survey of prescribers in South Africa, concerns were expressed about the availability of codeine OTC and the lack of data sources to examine its use [46]. The availability of non-prescribed codeine in South Africa may also have ramifications for neighbouring countries that restrict access. For example, reports in Zimbabwe suggest that codeine-containing cough syrup was being illegally smuggled in from South Africa and sold on the streets after being outlawed in 2015 [48]. However, there are limited data in many countries on the prevalence of such activities and the extent of codeine use and misuse. The public in Ireland spent the most on OTC codeine products and had the secondlargest sales volume. Concerns regarding public access to codeine and its misuse are well reported in Ireland [49,50]. However, a study examining hospital presentations involving intentional drug overdoses between 2007 and 2013 in Ireland reported a 20% decrease in codeine-related overdoses following new guidance for pharmacists in 2010 [51]. Despite this guidance, the sales of codeine in Ireland remained high in our study. According to IQVIA's data, Japan had the largest increase in sales, which may have been partly driven by Japan's reclassification process for OTC medicines in 2015 [52]. In contrast, sales fell considerably in France, which can be attributed to the decree signed by the French government in July 2017 that made codeine prescription-only with

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

immediate effect [27]. In South Africa, Canada, Switzerland, Ireland, and the UK, governments have proposed or are considering plans to do likewise [53–56], but in the meantime, many people in these countries may be self-medicating and unknowingly developing codeine dependency or addiction. Studies assessing the effect of rescheduling codeine to prescription-only in Australia showed a reduction in all codeine-related poisonings and no change in calls to poisons centres or sales of highstrength (>15 mg) prescribed codeine after reclassification [31,57]. The success of Australia's rescheduling suggests that governments worldwide should make codeine prescription-only. However, since many low- and middle-income countries experience barriers to accessing opioids [58–60], the WHO recommends that codeine should not be rescheduled and for codeine to be included in essential medicines lists [61]. If a consensus on the status of OTC codeine products cannot be reached, data should be collected globally to monitor its use and harms. Changes to regulations of OTC codeine and differences in trade exemptions, agreements, and disclosures of commercial interests at the country level may explain some of the variations in sales and expenditure [25]. For example, the public in Ireland, the UK, Croatia, and Japan spent more on OTC codeine products than South Africa despite their large sales volume. In countries such as Germany and the USA, which had high rates of prescribed opioids [60], mean sales of OTC codeine products were low. However, our figures included various formulations of codeine available OTC and depended on the coverage of data from IQVIA during the study period. Thus, it is difficult to determine whether the variation in sales represents real differences between countries.

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

Strengths and limitations We preregistered our study protocol and shared our statistical code and study materials where possible [41,42,44]. We used dosage units to combine liquid and solid forms, accounted for population increases over the study period and adjusted for IOVIA's coverage of data. The figures represent population-level sales and expenditure of OTC codeine in 31 countries, providing the best available proxy for actual use. However, many other countries sold codeine OTC during our study period, including Australia [32], which was not provided by *IQVIA* when we requested the data. Due to such data's commercial nature, IOVIA also withheld methodological information about the data, such as their formulation for calculating dosage units and conversion to GBP for other currencies. IQVIA's coverage and the completeness of data may have also affected trends; the percentages on data coverage was provided at single time points, which may not accurately represent changes over time. Sales represented products for adults, although we calculated rates using population statistics for all age groups, including children. Codeine-containing products may also be purchased in large quantities from online pharmacies or the black market [62], not captured in these data. **Implications** Since access to data on OTC codeine sales has previously been difficult to assess, our study provides one of the first estimates of the amount of codeine sold OTC in the 31 included countries. This information could inform future reviews of codeine by the WHO's Expert Committee on Drug Dependence [25] and international policies such as the rescheduling of codeine in the 1961 Single Convention on Narcotics Drugs.

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

However, better access to OTC sales data is still required. Amendments to medicines legislation in the UK shows how such data could be collected. The Misuse of Drugs Regulation 2001, the Medicines for Human Use (Administration and Sale or Supply) (Miscellaneous Amendments) Order 2007, and the Medicines (Sale or Supply) (Miscellaneous Provisions Amendment Regulations 2007) were updated to require pharmacies to submit counts of private prescriptions for Schedule 2 and Schedule 3 controlled drugs to the National Health Service (NHS) Prescription Services for analysis, audit, and monitoring [63,64]. A similar system could be enforced through a public health organisation such as the WHO or the International Narcotics Control Board (INCB), which already collects governments' annual drug statistics on codeine [65]. Such data could then be used by governments and researchers to monitor sales of OTC codeine and measure the impact of regulatory changes. **Conclusions** Codeine is one of the most widely accessible and used opioids worldwide. However, monitoring its use and preventing its misuse as an OTC product is a public health challenge. Healthcare professionals should ask their patients about their use of OTC products. Public health measures are needed to identify and prevent codeine misuse and increase awareness and education of the harms of codeine, particularly in young adults. Governments should review policies to improve the collection of sales data, and the safety of products sold OTC containing codeine.

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

Supplementary material Supplement 1: Supplementary tables and figures Supplement 2: STROBE reporting checklist **Declarations Funding** This research was supported by the Primary Care Research Trust of Birmingham and Midlands Research Practices Consortium who provided the funding to purchase the sales data from IQVIA. **Competing interests** GCR was financially supported by the National Institute for Health Research (NIHR) School for Primary Care Research (SPCR), the Naji Foundation, and the Rotary Foundation to study for a Doctor of Philosophy (2017-2020), but no longer has any financial COIs. GCR is an Associate Editor of BMJ Evidence Based Medicine. JKA has published articles and edited textbooks on adverse drug reactions and interactions and has often given medicolegal advice, including appearances as an expert witness in coroners' courts, often dealing with the adverse effects of opioids. BM works for NHS England as a pharmacist adviser. BG has received research funding from the Laura and John Arnold Foundation, the NIHR, the NIHR SPCR, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK (HDR UK), the Health Foundation, and the World Health Organisation (WHO); he also receives personal income from speaking

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

and writing for lay audiences on the misuse of science. FDRH acknowledges part support from the NIHR SPCR, the NIHR Applied Research Collaboration (ARC) Oxford Thames Valley, and the NIHR Oxford OUH BRC. CH is an NIHR Senior Investigator and has received expenses and fees for his media work, expenses from the WHO, FDA, and holds grant funding from the NIHR SPCR and the NIHR SPCR Evidence Synthesis Working Group [Project 380], the NIHR BRC Oxford and the WHO. On occasion, CH receives expenses for teaching EBM and is also paid for his GP work in NHS out of hours (contract with Oxford Health NHS Foundation Trust). CH is the Director of the CEBM. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Availability of data and material Study materials are available on an open repository [44] (https://osf.io/yt6bf/). We cannot openly share the data owing to contractual agreements with IQVIA, but the data can be accessed directly from IQVIA, which will require a fee. Code availability Our statistical code is openly available at GitHub [41] (https://github.com/georgiarichards/otc_codeine). **Authors' contributions** GCR devised the research question, designed the methods, wrote the protocol, conducted a literature search, sourced the data, cleaned, managed, and analysed the data, created the figures, and wrote the first draft of the manuscript. JKA and CH

reviewed the protocol and preliminary findings and provided supervisory support.

FDRH reviewed the protocol and facilitated the grant application. BM reviewed preliminary findings and contributed to the interpretation of data. BG provided supervisory support. All authors read and approved the final version.

Ethics approval

Not applicable

Consent to participate

Not applicable

Consent to publication

All authors read and approved the final manuscript and consent to submit the manuscript for publication.

References

- 411 1. Curtis HJ, Croker R, Walker AJ, Richards GC, Quinlan J, Goldacre B. Opioid
- 412 prescribing trends and geographical variation in England, 1998-2018: a retrospective
- database study. Lancet Psych [Internet]. 2019;6:140–50. Available from:
- 414 http://dx.doi.org/10.1016/S2215-0366(18)30471-1
- 415 2. Goodman-Meza D, Friedman J, Kalmin MM, Aguilar-Posada E, Seamans MJ,
- 416 Velazquez-Moreno S, et al. Geographical and socioeconomic disparities in opioid
- 417 access in Mexico, 2015–19: a retrospective analysis of surveillance data. Lancet Public
- 418 Heal [Internet]. 2021;6:e88–96. Available from: https://doi.org/10.1016/S2468-
- 419 2667(20)30260-7
- 420 3. Kalkman GA, Kramers C, Van Dongen RT, Van Den Brink W, Schellekens A.
- Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source
- database study. Lancet Public Heal [Internet]. 2019;4:498–505. Available from:
- 423 https://doi.org/10.1016/S2468-2667(19)30128-8
- 424 4. Krawczyk N, Greene MC, Zorzanelli R, Bastos FI. Rising trends of prescription
- opioid sales in contemporary Brazil, 2009-2015 [Internet]. Am. J. Public Health. 2018.
- 426 Available from: 10.2105/AJPH.2018.304341
- 427 5. Lambert AP. Life-threatening hypokalaemia from abuse of Nurofen Plus. J R Soc
- 428 Med [Internet]. 2005;98:21–21. Available from: 10.1258/jrsm.98.1.21
- 429 6. Frei MY, Nielsen S, Dobbin MDH, Tobin CL. Serious morbidity associated with
- 430 misuse of over □ the □ counter codeine–ibuprofen analgesics: a series of 27 cases. Med J
- 431 Aust [Internet]. 2010;193:294–6. Available from: 10.5694/j.1326-5377.2010.tb03911.x
- 432 7. Carney T, Wells J, Parry CDH, McGuinness P, Harris R, Van Hout MC. A
- 433 comparative analysis of pharmacists' perspectives on codeine use and misuse A three
- country survey. Subst Abus Treat Prev Policy [Internet]. 2018;13. Available from:
- 435 https://doi.org/10.1186/s13011-018-0149-2
- 436 8. Kimergård A, Foley M, Davey Z, Dunne J, Drummond C, Deluca P. Codeine use,
- 437 dependence and help-seeking behaviour in the UK and Ireland: an online cross-sectional
- 438 survey. QJM An Int J Med [Internet]. 2017;110:559–64. Available from:
- 439 10.1093/qjmed/hcx076
- 440 9. Agaba E, Agaba P, Wigwe C. Use and abuse of analgesics in Nigeria: a community
- 441 survey. Niger J Med. 2004;13:379–82.

- 442 10. Orriols L, Gaillard J, Lapeyre-Mestre M, Roussin A. Evaluation of abuse and
- dependence on drugs used for self-medication: A pharmacoepidemiological pilot study
- based on community pharmacies in France. Drug Saf [Internet]. 2009;32:859–73.
- 445 Available from: 10.2165/11316590-000000000-00000
- 446 11. Cooper RJ. "I can" t be an addict. I am.' Over-the-counter medicine abuse: A
- qualitative study. BMJ Open [Internet]. 2013;3:2913. Available from:
- 448 10.1136/bmjopen-2013-002913
- 12. Van Hout MC, Rich E, Dada S, Bergin M. "Codeine Is My Helper": Misuse of and
- 450 Dependence on Codeine-Containing Medicines in South Africa. Qual Health Res
- 451 [Internet]. 2017;27. Available from: 10.1177/1049732315613764
- 452 13. Kinnaird E, Kimergård A, Jennings S, Drummond C, Deluca P. From pain treatment
- 453 to opioid dependence: A qualitative study of the environmental influence on codeine
- use in UK adults. BMJ Open [Internet]. 2019;9:e025331. Available from:
- 455 10.1136/bmjopen-2018-025331
- 456 14. Roxburgh A, Hall WD, Burns L, Pilgrim J, Saar E, Nielsen S, et al. Trends and
- 457 characteristics of accidental and intentional codeine overdose deaths in Australia. Med J
- 458 Aust. Australasian Medical Publishing Co. Ltd; 2015;203:299.e1-299.e7.
- 459 15. Schifano F, Zamparutti G, Zambello F, Oyefeso A, Deluca P, Balestrieri M, et al.
- 460 Review of deaths related to analgesic- and cough suppressant-opioids; England and
- Wales 1996-2002 [Internet]. Pharmacopsychiatry. 2006. p. 185–91. Available from:
- 462 10.1055/s-2006-949149
- 463 16. Mill D, Johnson JL, Cock V, Monaghan E, Hotham ED. Counting the cost of over-
- 464 the-counter codeine containing analgesic misuse: A retrospective review of hospital
- admissions over a 5 year period. Drug Alcohol Rev [Internet]. 2018;37:247–56.
- 466 Available from: 10.1111/dar.12595
- 17. Derry S, Moore RA, McQuay HJ. Single dose oral codeine, as a single agent, for
- acute postoperative pain in adults. Cochrane Database Syst Rev [Internet]. 2010;
- 469 Available from: 10.1002/14651858.cd008099.pub2
- 470 18. Omar MI, Alexander CE. Drug treatment for faecal incontinence in adults [Internet].
- 471 Cochrane Database Syst. Rev. 2013. Available from:
- 472 10.1002/14651858.CD002116.pub2
- 473 19. Molassiotis A, Bailey C, Caress A, Tan JY. Interventions for cough in cancer

- 474 [Internet]. Cochrane Database Syst. Rev. 2015. Available from:
- 475 http://doi.wiley.com/10.1002/14651858.CD007881.pub3
- 476 20. Derry S, Karlin SM, Moore RA. Single dose oral ibuprofen plus codeine for acute
- postoperative pain in adults [Internet]. Cochrane Database Syst. Rev. 2015. Available
- 478 from: http://doi.wiley.com/10.1002/14651858.CD010107.pub3
- 479 21. Toms L, Derry S, Moore RA, McQuay HJ. Single dose oral paracetamol
- 480 (acetaminophen) with codeine for postoperative pain in adults [Internet]. Cochrane
- 481 Database Syst. Rev. 2009. Available from:
- 482 http://doi.wiley.com/10.1002/14651858.CD001547.pub2
- 483 22. Moore RA, Wiffen PJ, Derry S, Maguire T, Roy YM, Tyrrell L. Non-prescription
- 484 (OTC) oral analgesics for acute pain an overview of Cochrane reviews [Internet].
- 485 Cochrane Database Syst. Rev. 2015. Available from:
- 486 http://doi.wiley.com/10.1002/14651858.CD010794.pub2
- 487 23. Abdel Shaheed C, Maher CG, McLachlan AJ. Efficacy and Safety of Low-dose
- 488 Codeine-containing Combination Analgesics for Pain. Clin J Pain [Internet].
- 489 2019;35:836–43. Available from: 10.1097/AJP.0000000000000746
- 490 24. Frei MY, Nielsen S, Dobbin MDH, Tobin CL. Serious morbidity associated with
- 491 misuse of over-the-counter codeine-ibuprofen analgesics: A series of 27 cases. Med J
- 492 Aust [Internet]. 2010;193:294–6. Available from: 10.5694/j.1326-5377.2010.tb03911.x
- 493 25. WHO. Pre-Review Report: Preparations of codeine listed in Schedule III of the 1961
- 494 Single Convention on Narcotic Drugs [Internet]. Geneva; 2019 Oct. Available from:
- 495 https://www.who.int/medicines/access/controlled-substances/Final_codeine.pdf
- 496 26. United Nations. United Nations Single Convention on Narcotic Drugs, 1961
- 497 [Internet]. 1961 [cited 2021 Jan 20]. Available from:
- 498 https://www.emcdda.europa.eu/drugs-library/single-convention-narcotic-drugs-1961_en
- 499 27. Wilkes D. France restricts dextromethorphan and codeine [Internet]. OTC Toolbox.
- 500 2017 [cited 2021 Jan 24]. Available from: https://www.otctoolbox.com/industry-
- 501 news/france-restricts-dextromethorphan-and-codeine
- 502 28. Kirby T. The end of over-the-counter codeine in Australia. Lancet [Internet]. 2018;
- Available from: 10.1002/pds.3931/abstract
- 504 29. Foley M, Harris R, Rich E, Rapca A, Bergin M, Norman I, et al. The availability of
- over-the-counter codeine medicines across the European Union. Public Health

- 506 [Internet]. 2015;129:1465–70. Available from: 10.1016/j.puhe.2015.06.014
- 30. Lo MY, Ong MW, Lin JG, Sun WZ. Codeine consumption from over-the-counter
- anti-cough syrup in Taiwan: A useful indicator for opioid abuse. Acta Anaesthesiol
- 509 Taiwanica [Internet]. 2015;53:135–8. Available from: 10.1016/j.aat.2015.10.001
- 31. Cairns R, Schaffer AL, Brown JA, Pearson S, Buckley NA. Codeine use and harms
- in Australia: evaluating the effects of re scheduling. Addiction [Internet].
- 512 2020;115:451–9. Available from: 10.1111/add.14798
- 32. Gisev N, Nielsen S, Cama E, Larance B, Bruno R, Degenhardt L. An ecological
- study of the extent and factors associated with the use of prescription and over-the-
- 515 counter codeine in Australia. Eur J Clin Pharmacol [Internet]. 2016;72:469–94.
- 516 Available from: 10.1007/s00228-015-1995-8
- 517 33. Consumer Health IQVIA [Internet]. [cited 2020 Jun 12]. Available from:
- 518 https://www.iqvia.com/solutions/industry-segments/consumer-health
- 34. Hsia Y, Sharland M, Jackson C, Wong ICK, Magrini N, Bielicki JA. Consumption
- of oral antibiotic formulations for young children according to the WHO Access,
- Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-
- income and high-income countries. Lancet Infect Dis [Internet]. 2019;19:67–75.
- 523 Available from: 10.1016/S1473-3099(18)30547-4
- 524 35. Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, et al.
- 525 Comprehensive comparative effectiveness and safety of first-line antihypertensive drug
- 526 classes: a systematic, multinational, large-scale analysis. Lancet [Internet].
- 527 2019;394:1816–26. Available from: 10.1016/S0140-6736(19)32317-7
- 36. Guy GP, Haegerich TM, Evans ME, Losby JL, Young R, Jones CM. Vital Signs:
- 529 Pharmacy-Based Naloxone Dispensing United States, 2012–2018. MMWR Morb
- 530 Mortal Wkly Rep [Internet]. NLM (Medline); 2019 [cited 2020 Jun 12];68:679–86.
- Available from:
- http://www.cdc.gov/mmwr/volumes/68/wr/mm6831e1.htm?s_cid=mm6831e1_w
- 37. The World Bank. Population data [Internet]. 2019 [cited 2020 May 28]. Available
- 534 from:
- 535 https://data.worldbank.org/indicator/SP.POP.TOTL?end=2018&start=1960&view=char
- 536
- 537 38. PANDAS Development Team. pandas-dev/pandas: PANDAS. Zenodo; 2020.

- 39. Waskom M. mwaskom/seaborn. Zenodo; 2020.
- 40. Hunter J. Matplotlib: a 2D graphics environment. Comput Sci Eng. 2009;9:90–5.
- 41. Richards G. georgiarichards/otc_codeine [Internet]. GitHub. 2020 [cited 2021 Apr
- 3]. p. https://doi.org/10.5281/zenodo.5720700. Available from:
- 542 https://github.com/georgiarichards/otc_codeine
- 42. Richards G. Sales of over-the-counter (OTC) codeine-containing products in 31
- countries, 2013-2019 [Internet]. OSF Regist. 2020 [cited 2021 Apr 3]. Available from:
- 545 https://osf.io/ay4mc
- 43. Richards GC, Mahtani KR, Goldacre B, Heneghan C. 135 Trends and variation in
- 547 the sales of over-the-counter analgesics: a protocol for a retrospective database study
- and policy review. BMJ Evidence-Based Med [Internet]. 2018. p. A63.2-A64. Available
- 549 from: 10.1136/bmjebm-2018-111070.135
- 44. Richards GC, Hobbs R, Aronson JK, Heneghan C. Sales of over-the-counter (OTC)
- codeine-containing products [Internet]. OSF. 2021 [cited 2021 Jan 4]. Available from:
- 552 https://osf.io/yt6bf/
- 45. Kamerman PR, Bradshaw D, Laubscher R, Pillay-Van Wyk V, Gray GE, Mitchell
- D, et al. Almost 1 in 5 South African adults have chronic pain: a prevalence study
- conducted in a large nationally representative sample. Pain [Internet]. 2020;161:1629–
- 556 35. Available from: 10.1097/J.PAIN.000000000001844
- 46. Foley M, Carney T, Rich E, Dada S, Mburu C, Parry C. A study of medical
- 558 professionals' perspectives on medicines containing codeine in South Africa. South
- African J Psychiatry [Internet]. 2018;24. Available from:
- 560 10.4102/sajpsychiatry.v24i0.1162
- 561 47. Dada S, Burnhams NH, van Hout MC, Parry CDH. Codeine misuse and dependence
- 562 in South Africa learning from substance abuse treatment admissions. South African
- 563 Med J [Internet]. 2015;105:776–9. Available from: 10.7196/SAMJnew.8172
- 48. VICE Video. Zimbabwe's Codeine Cough Syrup Epidemic [Internet]. 2018 [cited
- 565 2021 Feb 1]. Available from: https://video.vice.com/en_uk/video/vice-zimbabwes-
- 566 codeine-cough-syrup-epidemic-1-104/5c373790be407707904345c1
- 567 49. Foley M, Carney T, Harris R, Fitzpatrick E, Rapca-Veillet A, Van Hout MC.
- 568 Medicines containing codeine: perspectives of medical professionals in the Republic of
- 569 Ireland. Ir J Med Sci [Internet]. 2017;186:555–63. Available from: 10.1007/s11845-

- 570 016-1546-z
- 57. So. Van Hout MC, Horan A, Santlal K, Rich E, Bergin M. "Codeine is my companion":
- 572 Misuse and dependence on codeine containing medicines in Ireland. Ir J Psychol Med
- 573 [Internet]. 2018;35:275–88. Available from: 10.1017/ipm.2015.60
- 51. Birchall E, Perry IJ, Corcoran P, Daly C, Griffin E. The impact of guidance on the
- supply of codeine-containing products on their use in intentional drug overdose. Eur J
- Public Health [Internet]. Oxford University Press (OUP); 2021 [cited 2021 Jun 2];1–6.
- 577 Available from: https://academic.oup.com/eurpub/advance-
- 578 article/doi/10.1093/eurpub/ckab082/6285556
- 579 52. Nomura K, Kitagawa Y, Yuda Y, Takano-Ohmuro H. Medicine reclassification
- processes and regulations for proper use of over-the-counter self-care medicines in
- Japan. Risk Manag Healthc Policy [Internet]. 2016;9:173–83. Available from:
- 582 10.2147/RMHP.S98099
- 583 53. de Villiers J. Here are the over-the-counter medicines you may need a prescription
- for in future including Adcodol and Nurofen Plus [Internet]. Bus. Insid. SA. 2020
- [cited 2021 Jan 25]. Available from: https://www.businessinsider.co.za/codeine-
- 586 containing-medicines-in-south-africa-to-be-affected-by-south-african-health-products-
- regulatory-authoritys-up-scheduling-move-2020-1
- 588 54. Ridley D. Swiss experts advise codeine reverse-switch [Internet]. LinkedIn. 2018
- 589 [cited 2021 Jan 25]. Available from: https://www.linkedin.com/pulse/swiss-experts-
- 590 advise-codeine-reverse-switch-david-ridley/
- 59. MHRA. UK regulator strengthens opioid warnings [Internet]. Vigil. Saf. alerts
- 592 Guid. 2020 [cited 2021 Jan 20]. Available from:
- 593 https://www.gov.uk/government/news/uk-regulator-strengthens-opioid-warnings
- 594 56. Government of Canada. Forward Regulatory Plan 2019-2021: Regulations
- 595 Amending the Narcotic Control Regulations under the Controlled Drugs and Substances
- Act to make all products containing codeine available by prescription only while
- ensuring access to these medications [Internet], 2019 [cited 2021 Jan 28]. Available
- from: https://www.canada.ca/en/health-canada/corporate/about-health-
- 599 canada/legislation-guidelines/acts-regulations/forward-regulatory-plan/plan/codeine-
- 600 prescription.html
- 57. Schaffer AL, Cairns R, Brown JA, Gisev N, Buckley NA, Pearson SA. Changes in

- sales of analgesics to pharmacies after codeine was rescheduled as a prescription only
- medicine. Med J Aust. John Wiley and Sons Inc.; 2020;212:321–7.
- 58. Fadhil I, Lyons G, Payne S. Barriers to, and opportunities for, palliative care
- development in the Eastern Mediterranean Region [Internet]. Lancet Oncol. 2017. p.
- 606 e176–84. Available from: 10.1016/S1470-2045(17)30101-8
- 59. Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, et al. Use of and
- barriers to access to opioid analgesics: A worldwide, regional, and national study.
- 609 Lancet [Internet]. 2016;387. Available from: 10.1016/S0140-6736(16)00161-6
- 610 60. Richards GC, Aronson JK, Mahtani KR, Heneghan C. Global, regional, and national
- consumption of controlled opioids: a cross-sectional study of 214 countries and non-
- 612 metropolitan territories. Br J Pain [Internet]. 2021; Available from:
- 613 https://doi.org/10.1177/20494637211013052
- 61. Richards GC, Aronson JK, Heneghan C, Mahtani KR, Koshiaris C, Persaud N.
- Relation between opioid consumption and inclusion of opioids in 137 national essential
- medicines lists. BMJ Glob Heal [Internet]. 2020;5:1–8. Available from: 10.1136/bmjgh-
- 617 2020-003563
- 618 62. Marsh S. "I could get 500 tablets a month": the ease of buying opiates online
- [Internet]. Guard. 2019 [cited 2021 Jan 24]. Available from:
- 620 https://www.theguardian.com/society/2019/apr/26/i-could-get-500-tablets-a-month-
- 621 ease-of-buying-opiates-online
- 622 63. NHS England. The Controlled Drugs (Supervision of Management and Use)
- 623 Regulations 2013 [Internet]. Single Oper. Model. 2013 [cited 2021 Apr 19]. Available
- from: https://www.england.nhs.uk/wp-content/uploads/2013/11/som-cont-drugs.pdf
- 625 64. PSNC. Controlled Drug prescription forms and validity [Internet]. Pharm. Serv.
- 626 Negot. Comm. 2020 [cited 2021 Apr 19]. Available from:
- 627 https://psnc.org.uk/dispensing-supply/dispensing-controlled-drugs/controlled-drugs
- 628 prescription-forms-and-validity/
- 629 65. INCB. Narcotic Drugs Estimated World Requirements for 2020 Statistics for
- 630 2018 [Internet]. Vienna; 2019 [cited 2020 Oct 25]. Available from:
- 631 https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-
- 632 2019.06-eng.pdf

Table 1: Mean sales of OTC codeine-containing products and public expenditure reported by *IQVIA* between April 2013 and March 2019 in 31 countries, and adjusted for *IQVIA*'s data coverage, in alphabetical order

Country	No. of products	Coverage (%)	mean dosage units per 1000 population (SD)		mean public expenditure, £ per 1000 population (SD)	
			Reported sales	Adjusted* sales	Reported expenditure	Adjusted* expenditure
Argentina	1	73	0.111 (0.19)	0.152 (0.26)	0.002 (0.004)	0.003 (0.005)
Belgium	32	71	497 (849)	700 (1195)	40 (40)	56 (57) 0.0008 (0.002)
Brazil	3	53	0.0018 (0.003)	0.0034 (0.005)	0.0004 (0.0008)	0.0008 (0.002)
Bulgaria	8	85	2537 (163)	2984 (192)	323 (40)	380 (47)
Canada	4	87	117 (44)	135 (51)	7 (6)	8 (7)
Croatia	2	67	7084 (469)	10573 (699)	1254 (93)	1871 (138)
Estonia	5	88	5305 (1081)	6029 (1228)	1032 (273)	1173 (310)
Finland	2	73	2996 (310)	4104 (424)	106 (9)	146 (12)
France	36	79	15717 (10558)	19895 (13365)	743 (449)	941 (569)
Germany	28	86	0.770 (0.18)	0.895 (0.2)	0.136 (0.07)	0.159 (0.08)
Greece	1	60	27 (16)	45 (27)	1 (0.76)	2 (1.27)
Ireland	23	80	23621 (2566)	29526 (3207)	5741 (624)	7176 (781)
Italy	2	37	0.0068 (0.013)	0.0182 (0.04)	0.0018 (0.004)	0.0048 (0.009)
Japan	28	56	6870 (4780)	12268 (8536)	869 (659)	1552 (1176)

Latvia	19	92	15468 (682)	16813 (741)	728 (178)	791 (193)
Lithuania	2	92	865 (169)	940 (183)	266 (75)	289 (82)
Mexico	2	61	221 (89)	362 (145)	8 (3)	12 (5)
Netherlands	7	58	2668 (299)	4600 (516)	118 (10)	204 (18)
Poland	19	75	6921 (598)	9228 (797)	491 (89)	655 (119)
Portugal	2	58	0.007 (0.01)	0.012 (0.18)	0.0008 (0.001)	0.0014 (0.002)
Romania	15	85	2969 (191)	3493 (225)	329 (63)	987 (75)
Russia	24	65	96 (41)	148 (63)	18 (8)	27 (12)
Serbia	5	100	8505 (451)	8505 (451)	692 (79)	692 (79)
Slovakia	5	85	1205 (74)	1418 (87)	323 (42)	380 (49)
Slovenia	2	97	1364 (93)	1407 (96)	309 (24)	319 25)
South Africa	157	86	31133 (3154)	36202 (3667)	1266 (265)	1472 (308)
Spain	2	48	0.0015 (0.004)	0.0032 (0.008)	0.0001 (0.0003)	0.0002 (0.0006)
Switzerland	44	75	5051 (1473)	6734 (1965)	675 (80)	900 (107)
Thailand	3	22	6 (3)	28 (12)	0.117 (0.06)	0.532 (0.29)
UK	83	67	11500 (333)	17164 (497)	1599 (97)	2387 (144)
USA	3	47	57 (26)	120 (55)	4 (1)	9 (2.3)

^{*}Adjusted metrics were calculated by dividing IQVIA's reported values by the coverage percentages provided by *IQVIA* OTC: over-the-counter; SD: standard deviation









